Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market

When you hear that a drug like Humira is about to lose its patent protection, you might assume biosimilars will flood the market right away. But in the U.S., that’s not how it works. Even after the original patent expires, biosimilars can’t just show up and start selling. There’s a legal and regulatory maze that delays competition for years - sometimes more than a decade. And this isn’t just a technicality. It directly affects how much patients pay for life-changing treatments.

How Long Must You Wait for a Biosimilar?

The U.S. doesn’t treat biologics like regular pills. A biologic - think Humira, Enbrel, or Keytruda - is made from living cells, not chemicals. That makes copying it far harder than making a generic version of, say, ibuprofen. To balance innovation and access, Congress passed the Biologics Price Competition and Innovation Act (BPCIA) in 2010. It created a special path for biosimilars, but with strict rules.

Here’s the timeline in plain terms:

• Year 0: The brand-name biologic gets FDA approval.
• Year 4: Biosimilar companies can finally submit their application to the FDA.
• Year 12: The FDA can approve the first biosimilar.

That’s 12 years of market exclusivity - no competition allowed. Even if the original patent expires at year 8, biosimilars still can’t be sold until year 12. This isn’t a patent extension. It’s a separate, congressionally mandated exclusivity period. And it’s longer than most other countries. The EU gives 10 years of data protection plus 1 year of market exclusivity - 11 total. The U.S. gives 12. Japan also gives 12. But the difference in timing has real consequences.

Why the U.S. Lags Behind Europe

Humira was approved in the U.S. in 2002. In Europe, biosimilars started arriving in 2018 - six years later. But in the U.S., the first biosimilar didn’t hit the market until 2023. That’s a 21-year gap between the drug’s launch and biosimilar entry. During that time, the price of Humira in the U.S. rose 470%. In Europe, where biosimilars entered earlier, prices dropped by 60% or more.

Why the delay? It’s not just the 12-year clock. It’s also the legal battles. Companies like AbbVie, which makes Humira, piled on hundreds of patents - over 160, according to research from I-MAK. These weren’t all about the core molecule. Many covered delivery devices, dosing schedules, or manufacturing tweaks. Each one became a potential lawsuit.

This tactic, called a “patent thicket,” is designed to scare off competitors. Even if a biosimilar company clears the FDA’s scientific hurdles, they still have to fight through years of litigation. The “patent dance” - a formal, court-mandated exchange of information between the brand and biosimilar maker - often drags on for 2 to 5 years before a single product can even be approved.

The Cost of Delay

The impact isn’t theoretical. In 2022, the Arthritis Foundation reported that U.S. patients paid an average of $3,000 per month for Humira. In Germany, the same drug cost $400. That’s not because German healthcare is better. It’s because biosimilars entered sooner.

Patients with rheumatoid arthritis, Crohn’s disease, or psoriasis often can’t switch treatments easily. If a biosimilar isn’t available, they’re stuck paying the brand price - even if they’re on Medicaid or Medicare. Pharmacists surveyed by the National Community Pharmacists Association found that 63% of their patients had skipped doses or stopped treatment entirely because they couldn’t afford the drug.

And it’s not just Humira. Between 2025 and 2034, 118 biologics will lose exclusivity in the U.S. - a $234 billion market. But only 12 of them currently have biosimilars in development. Why? Because the cost to develop one is staggering.

Biosimilar Development: It’s Not Just Science

Making a generic pill costs $1-2 million and takes about two years. Making a biosimilar? It takes $100 million to $250 million and 5 to 10 years. Why? Because biologics are made from living cells. Even tiny changes in how they’re grown, stored, or shipped can affect how they work in the body.

The FDA requires proof that a biosimilar is “highly similar” with “no clinically meaningful differences” in safety, purity, or potency. That means:

• Thousands of lab tests comparing the biosimilar to the original
• Pharmacokinetic studies showing how the body absorbs and processes the drug
• Potentially, clinical trials with hundreds of patients

And that’s just to get approval. Then comes the hard part: getting doctors and insurers to switch. Many still think biosimilars are “inferior.” Some states have laws that require doctors to get special permission before substituting a biosimilar. Others don’t allow substitution at all.

The Biosimilar Void

There’s a growing crisis called the “biosimilar void.” It’s when a biologic is about to lose exclusivity - but no one is ready to make a biosimilar. The Biosimilars Council found that 88% of expiring biologics with orphan drug status (for rare diseases) have no biosimilar in development. That includes treatments for cancers, autoimmune disorders, and genetic conditions.

Why? Because these drugs are complex. They’re made from antibodies, gene therapies, or cell-based products. The manufacturing is so intricate, and the patient population so small, that companies don’t see a financial return. Pfizer’s data shows that developing a biosimilar for an antibody-drug conjugate can cost over $250 million. If only 5,000 patients in the U.S. need it, the math doesn’t add up.

Meanwhile, the FDA has tried to help. Their 2022 Biosimilars Action Plan promised to improve communication, speed up reviews, and support competition. But progress has been slow. Since 2015, the U.S. has approved only 38 biosimilars. Europe has approved 88.

What’s Next?

There’s no easy fix. The 12-year exclusivity period is written into law. The patent dance is a legal requirement. And developing biosimilars for complex drugs remains expensive and risky.

But change is coming. More companies are entering the space. The first biosimilar for a gene therapy is expected by 2027. Some states are changing laws to allow automatic substitution. And Congress is starting to listen. The Congressional Budget Office estimated that if barriers are lowered, biosimilars could save the U.S. healthcare system $158 billion over the next decade.

The question isn’t whether biosimilars will enter the market. They will. The question is: how long will patients have to wait? And how much will they pay in the meantime?